Enveric Biosciences, Inc.

ENVB

Explore Our Financial Data > Companies > Enveric Biosciences, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ENVB
CIK0000890821
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address4851 TAMIAMI TRAIL N, SUITE 200, NAPLES, FL, 34103
Website enveric.com
Phone239-302-1707
CEOJoseph Tucker
Employees20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-8.22 million
Net Income$-8.22 million
Net Income to Common$-11.58 million
EPS$-7.67
View All
Balance Sheet
Cash$4.91 million
Assets$5.52 million
Liabilities$460,676.00
Common Equity$5.06 million
Liabilities & Equity$5.52 million
View All
Cash Flow Statement
Net Income$-8.22 million
Cash From Operating Activities$-8.01 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$8.63 million
Change in Cash$614,334.00
View All
Calculations
NOPAT$-5.75 million
EBITDA$-8.06 million
Price to EarningsN/A
Price to Book$1.16
ROE-183.12%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

CAMBRIDGE, Mass., June 02, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003.

Article Link

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

CAMBRIDGE, Mass., May 19, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further derisking its continued development for the chronic treatment of neuropsychiatric disorders.

Article Link

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

CAMBRIDGE, Mass., May 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update.

Article Link

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

CAMBRIDGE, Mass., May 13, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the ’361 patent), titled, "Carboxylated Psilocybin Derivatives and Methods of Using," pertaining to the Company’s EVM301 Series of molecules being d

Article Link

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

CAMBRIDGE, Mass., May 05, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduction in

Article Link